• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Prescription Drug Pricing: Cost & Control Concerns

Prescription Drug Pricing: Cost & Control Concerns

9781613246399
573,24 zł
515,91 zł Zniżka 57,33 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 515,91 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
The growing cost of brand-name prescription drugs can be a burden on patients, payers and providers of health care, particularly when price increases are large and occur suddenly. Controlling rising prescription drug prices helps to ensure that patients can afford medically necessary and sometimes life-saving medication, and to moderate costs for hospitals and third-party payers such as insurance plans and state and federal governments. This book examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.
Szczegóły produktu
73300
9781613246399
9781613246399

Opis

Rok wydania
2012
Numer wydania
1
Oprawa
twarda
Liczba stron
147
Wymiary (mm)
230.00 x 155.00
Waga (g)
380
  • Preface; Prescription Drugs:: Trends in Usual & Customary Prices for Commonly Used Drugs; Lack of Therapeutically Equivalent Drugs & Limited Competition May Contribute to Extraordinary Price Increases; Overview of Approaches to Control Prescription Drug Spending in Federal Programs; Opening Statement of U.S. Senator Amy Klobuchar, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Statement of Senator Charles E Schumer, Chairman, Joint Economic Committee, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Statement of Madeline M Carpinelli, Stephen W Schondelmeyer, PRIME Institute, College of Pharmacy, University of Minnesota, Before the Joint Economic Committee, Hearing on Extraordinary Price Increases in the Pharmaceutical Market; Testimony of Alan L Goldbloom, MD, President & CEO, Childrens Hospitals & Clinics of Minnesota, before the Joint Economic Committee, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Testimony of Danielle Foltz, before the Joint Economic Committee, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Entry Threats & Pricing in the Generic Drug Industry; Index.
Komentarze (0)